Compare ERNA & EEIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERNA | EEIQ |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 7.8M |
| IPO Year | 2021 | 2019 |
| Metric | ERNA | EEIQ |
|---|---|---|
| Price | $2.08 | $4.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.5K | 14.4K |
| Earning Date | 11-06-2026 | 06-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.15 |
| 52 Week High | $71.50 | $12.70 |
| Indicator | ERNA | EEIQ |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 53.60 |
| Support Level | N/A | $2.45 |
| Resistance Level | $4.72 | $4.83 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 21.52 | 25.30 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.